Saturday, February 25, 2023 3:00:41 PM
Gem,
If you have read my other posts, even I am am hypothesizing that he just might have found some "investors" to fork over that $5 million. The question that will remain is, at what cost to the company and shareholders?
We'll soon find out but what can't be debates is that Koos is not very good at managing the company.
There were high hopes that he'd get funding for P1 trials of HemaX once it got FDA approved. That never happened. Koos has a long history of failure when it comes to developing the pipeline and that's all that matters with biotechs.
Let's see what happens the week of March 6th.
Maybe the konman can prove me wrong just once.
If you have read my other posts, even I am am hypothesizing that he just might have found some "investors" to fork over that $5 million. The question that will remain is, at what cost to the company and shareholders?
We'll soon find out but what can't be debates is that Koos is not very good at managing the company.
There were high hopes that he'd get funding for P1 trials of HemaX once it got FDA approved. That never happened. Koos has a long history of failure when it comes to developing the pipeline and that's all that matters with biotechs.
Let's see what happens the week of March 6th.
Maybe the konman can prove me wrong just once.
FACTS are stubborn things
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
